Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT02157324 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02157324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02157324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Lead sponsor
Acerta Pharma BV
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 18, 2014
Completion date
April 1, 2026
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia